Hoth Therapeutics And Wise Systems International SRL Announces Joint Development To Utilize Artificial Intelligence For Drug Discovery; Nvidia BioNeMo Generative AI Platform Will Be Used To Accelerate The Training Of Models On Proprietary Data
Portfolio Pulse from Benzinga Newsdesk
Hoth Therapeutics has entered into a joint development agreement with Wise Systems International SRL to utilize Nvidia's BioNeMo AI platform for drug discovery. This collaboration aims to accelerate the training of models on proprietary data using generative AI.
June 10, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hoth Therapeutics has announced a joint development agreement with Wise Systems to use Nvidia's BioNeMo AI platform for drug discovery, which could enhance their R&D capabilities.
The partnership with Wise Systems and the use of Nvidia's advanced AI platform could significantly enhance Hoth Therapeutics' drug discovery process, potentially leading to faster and more efficient R&D outcomes.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Nvidia's BioNeMo AI platform will be used by Hoth Therapeutics and Wise Systems for drug discovery, showcasing the platform's applicability in biopharmaceutical R&D.
The use of Nvidia's BioNeMo AI platform in a new biopharmaceutical application underscores its versatility and could drive further interest and adoption in the healthcare sector.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 50